Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Abliva on the public offer from Pharming
Mandate

Vinge advises Abliva on the public offer from Pharming

December 16, 2024 Capital Markets and Public M&A

Pharming Technologies B.V., a wholly owned subsidiary of Pharming Group N.V., has announced a public offer to the shareholders of Abliva AB (publ). The total value of the offer is approximately SEK 725 million.

The Vinge team includes Christian Lindhé, Erik Sjöman, Martin Madsen Svanberg and Agaton Lindgren.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026